NeoPhore
Broadening cancer patient access to powerful disease-transforming immunotherapy
Founded 2017 · $12.2M raised
- Founded
- 2017
- Website
- neophore.com
- Total Funding
- $12.2M
- Last Round
- $12.2M Extension RoundFeb 2024
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
NeoPhore is an immuno-oncology company developing small-molecule cancer therapies that target the DNA mismatch-repair pathway. Its approach temporarily inhibits mismatch repair to make otherwise mismatch-repair-proficient tumors more responsive to immune checkpoint therapy. Founded after clinical research into durable immunotherapy responses, the company has developed assays and discovery technologies intended to advance first-in-class inhibitors into clinical testing.
Summary
NeoPhore is a Biotech company, founded in 2017. It has raised $12.2M in total across 1 round, most recently a $12.2M Extension Round in Feb 2024.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Feb 2024
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/neophore"><img src="https://indexed.vc/api/badge/company/neophore" alt="NeoPhore on Indexed.vc" width="260" height="76" /></a>